Nursing practice Ph.D. student Lindsey Adkinsson says "I really do believe in the power of primary care and prevention, and seeing patients who have a trusting relationship with their provider.”

Research co-led by Pepper Schedin, Ph.D., finds women diagnosed with breast cancer up to 10 years after giving birth have a higher risk of metastasis than childless women of the same age.

Jessica Castle, M.D., is quoted in a story about the high cost of insulin to treat diabetes.

Renee Edwards, M.D., M.B.A., is quoted as saying “Transplant healthcare providers like OHSU are obligated to select transplant candidates in an equitable manner while also being good stewards of a scare resource and precious gift,” in a letter to Oregon legislators about a proposal that would prevent medical providers from removing organ transplant candidates from waiting lists due to marijuana use.

The Royal Swedish Academy of Sciences announces that Brian Druker, M.D., and Dennis Slamon, M.D., Ph.D., are recipients for the 2019 Sjöberg prize for their “ground-breaking contributions to the clinical development of targeted therapy directed against genetic aberrations in cancer.”

Dan Hartung, Pharm.D., M.P.H., is quoted as saying “"The implications of the escalating high costs and prices really have been reductions in access, due to policies Part D put in place and out-of-pocket costs for patients" in a story about Medicare policies shifting the cost burden for multiple sclerosis drugs more on patients.

Anna Castilla, D.D.S., reports adults make up to 40 percent of her clients in a story about braces becoming more common for adults.

Highlights of a nearly 50-year career of John Barry, M.D., and the experience of his 2,500th kidney transplant patient, Mary Gale.

OHSU research program develops use of in-home technology to help older people maintain independence. “We’re very proud to have it in Oregon and at OHSU. It’s become a whole new world, and we’re very excited to be part of it,” says Jeffrey Kaye, M.D.

KIYATEC announces OHSU is enrolling newly diagnosed and relapsed ovarian cancer patients into the company’s 3-D PREDICT study, designed to predict response to cancer therapy prior to treatment.